Survey Finds Genetic Discrepancies in Nearly Half of Lab Mouse Samples
A study of laboratory mouse strains at major research repositories found nearly half of samples had genetic profiles that did not match their reported identities. The findings highlight gaps in quality control that could affect experimental results.
rnz.co.nzResearchers examined laboratory mouse strains maintained by major research repositories and identified genetic discrepancies in nearly half of the samples tested. The survey compared reported identities with actual genetic profiles. Many inconsistencies were minor, while others carried potential to change biological outcomes in experiments.
Discrepancies introduce hidden genetic variables that can undermine experimental validity and reproducibility. The study points to a need for improved verification procedures at repositories that supply mice to laboratories worldwide. The findings were published in a SciencePolicyArticle that details the scope of the mismatches and their possible effects on research outcomes.
Key Facts
Potential Impact
- 01
Laboratories may increase genetic verification of mouse strains before experiments.
- 02
Repositories could implement additional quality-control checks on strain identities.
Transparency Panel
Related Stories
NprWHO Director Visits Congo as Ebola Outbreak Spreads
The head of the World Health Organization arrived in Kinshasa to support efforts against a rare Ebola strain. Health workers face equipment shortages, community distrust, and armed conflict in affected provinces.
medpagetoday.comFDA Panel Recommends XFG Variant for Fall Covid Shots
Replimune will submit an application to the FDA for the third time. Pfizer and Innovent Biologics reached a collaboration agreement valued at up to $10.5 billion.
Benzinga Publishes Article on Biotech Stocks During Pandemic Recovery
Benzinga published an article titled 'Best Biotech Stocks Right Now' that addresses the sector's position during global recovery from the pandemic. The piece notes government institutions and professional traders are focusing on biotech companies for vaccine and booster developme…